Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)

Table 1

Baseline characteristics of the Dabi-ADP-1 and Dabi-ADP-2 study population.

Characteristics	Dabi-ADP-1			Dabi-ADP-2
	Dabigatran; (%)	Phenprocoumon; (%)	value	Dabigatran; (%)	Phenprocoumon; (%)	value
Age, years	69 ± 11	70 ± 13	0.89	71 ± 7	76 ± 8	0.06
Woman (%)	14 (40.0)	10 (28.6)	0.31	4 (18.2)	3 (12.5)	0.69
Arterial hypertension (%)	26 (74.3)	24 (68.6)	0.60	21 (95.5)	24 (100)	0.29
Diabetes mellitus (%)	3 (8.6)	9 (25.7)	0.11	5 (22.7)	9 (37.5)	0.28
Hypercholesterolemia (%)	23 (65.7)	23 (65.7)	>0.99	18 (81.8)	18 (75.0)	0.57
Prior myocardial infarction (%)	0 (0)	3 (8.6)	—	5 (22.7)	10 (41.7)	0.17
Prior bypass surgery (%)	1 (2.9)	1 (2.9)	>0.99	3 (13.6)	5 (20.8)	0.70
CHA2DS2-VASc score	2.8 ± 1.5	3.2 ± 1.6	0.25	4.0 ± 1.3	4.6 ± 1.0	0.13
Prior stroke (%)	0 (0)	1 (2.9)	—	1 (4.5)	1 (4.2)	1.0
Prior TIA (%)	0 (0)	1 (2.9)	—	0 (0)	1 (4.2)	—
Prior bleeding (%)	4 (11.4)	2 (5.7)	0.67	1 (4.5)	3 (12.5)	0.61
Medication at randomization
Aspirin (%)	12 (34.3)	13 (37.1)	0.80	20 (90.9)	24 (100)	0.13
Clopidogrel (%)	0	0		22 (100)	24 (100)	—
Statin (%)	11 (31.4)	18 (51.4)	0.09	20 (90.9)	24 (100)	0.13
PPI (%)	4 (11.4)	7 (20.0)	0.51	5 (25.0)	8 (33.3)	0.55